These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 25208859

  • 1. Stereotactic radiotherapy for neovascular age-related macular degeneration: year 2 results of the INTREPID study.
    Jackson TL, Chakravarthy U, Slakter JS, Muldrew A, Shusterman EM, O'Shaughnessy D, Arnoldussen M, Gertner ME, Danielson L, Moshfeghi DM, INTREPID Study Group.
    Ophthalmology; 2015 Jan; 122(1):138-45. PubMed ID: 25208859
    [Abstract] [Full Text] [Related]

  • 2. Stereotactic radiotherapy for neovascular age-related macular degeneration: 52-week safety and efficacy results of the INTREPID study.
    Jackson TL, Chakravarthy U, Kaiser PK, Slakter JS, Jan E, Bandello F, O'Shaughnessy D, Gertner ME, Danielson L, Moshfeghi DM, INTREPID Study Group.
    Ophthalmology; 2013 Sep; 120(9):1893-900. PubMed ID: 23490327
    [Abstract] [Full Text] [Related]

  • 3. Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET): fluorescein angiography and optical coherence tomography.
    Jackson TL, Dugel PU, Bebchuk JD, Smith KR, Petrarca R, Slakter JS, Jaffe GJ, Nau JA, CABERNET Study Group.
    Ophthalmology; 2013 Aug; 120(8):1597-603. PubMed ID: 23490325
    [Abstract] [Full Text] [Related]

  • 4. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Busbee BG, Ho AC, Brown DM, Heier JS, Suñer IJ, Li Z, Rubio RG, Lai P, HARBOR Study Group.
    Ophthalmology; 2013 May; 120(5):1046-56. PubMed ID: 23352196
    [Abstract] [Full Text] [Related]

  • 5. Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration (MERLOT): A Phase 3 Randomized Controlled Trial.
    Jackson TL, Desai R, Simpson A, Neffendorf JE, Petrarca R, Smith K, Wittes J, Lewis C, Membrey L, Haynes R, Costen M, Steel DH, Muldrew A, Chakravarthy U, Macular Epiretinal Brachytherapy versus Ranibizumab (Lucentis) Only Treatment (MERLOT) Study Group.
    Ophthalmology; 2016 Jun; 123(6):1287-96. PubMed ID: 27086023
    [Abstract] [Full Text] [Related]

  • 6. Stereotactic radiotherapy for wet age-related macular degeneration (INTREPID): influence of baseline characteristics on clinical response.
    Jackson TL, Shusterman EM, Arnoldussen M, Chell E, Wang K, Moshfeghi DM, INTREPID Study Group.
    Retina; 2015 Feb; 35(2):194-204. PubMed ID: 25102198
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Macular epiretinal brachytherapy in treated age-related macular degeneration (MERITAGE): month 12 optical coherence tomography and fluorescein angiography.
    Petrarca R, Dugel PU, Nau J, Slakter JS, Jaffe GJ, Jackson TL.
    Ophthalmology; 2013 Feb; 120(2):328-33. PubMed ID: 23178157
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Comparison of two intravitreal ranibizumab treatment schedules for neovascular age-related macular degeneration.
    Gupta B, Adewoyin T, Patel SK, Sivaprasad S.
    Br J Ophthalmol; 2011 Mar; 95(3):386-90. PubMed ID: 20693484
    [Abstract] [Full Text] [Related]

  • 13. Epimacular brachytherapy for neovascular age-related macular degeneration: a randomized, controlled trial (CABERNET).
    Dugel PU, Bebchuk JD, Nau J, Reichel E, Singer M, Barak A, Binder S, Jackson TL, CABERNET Study Group.
    Ophthalmology; 2013 Feb; 120(2):317-27. PubMed ID: 23174399
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Implications of the comparisons of age-related macular degeneration treatments trials on clinical practice: what have we learned?
    Do DV.
    Ophthalmology; 2013 May; 120(5 Suppl):S8-10. PubMed ID: 23642785
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.